Conference paper

Meloxicam - the balance of efficacy and safety

Jadranka Morović-Vergles ; Department for Clinical Immunology and Rheumatology, Clinic for Internal Medicine, Clinical Hospital “Dubrava”, Zagreb, Croatia

Abstract

NSAIDs remain the principal pharmacological agents used for symptom relief in patients with rheumatic disease. They represent the largest single group of drugs used worldwide. Given the large number of available NSAIDs, it is unsurprising that some differences exist among them with regard to mechanism of action, pharmacokinetics, and tolerability. How these differences affect the overall risks and benefits of treatment continues to be examined in clinical trials. Meloxicam is COX-2 selective NSAID with favourable gastrointestinal and thromboembolic safety profile.

Keywords

NSAID; meloxicam; safety profile

Hrčak ID:

125255

URI

https://hrcak.srce.hr/125255

Publication date:

17.10.2008.

Article data in other languages: croatian

Visits: 1.721 *